Nikegen aims at developing next-generation gene therapy drugs based on AAV vectors. Driven by advanced vector technologies, Nikegen overcomes the bottlenecks of AAV vectors in gene therapy development and expands new applications for AAV vectors.
Our strong scientific discovery and technology platform enable us a best partner for gene therapy company. We look forward to establish partnership with any long term partners. Nikegen and our partners, are able to get treatments to those in need around the world.
We welcome hearing from you if you would like more information about Nikegen.
For partnering information, please contact: bd@nikegen.com